Creat membership Creat membership
Sign in

Forgot password?

Confirm
  • Forgot password?
    Sign Up
  • Confirm
    Sign In
home > search

Now showing items 49 - 64 of 30489

  • Actualités du traitement de l’hépatite C

    Moal, Frédéric   Terrail, Nicolas  

    Download Collect
  • Traitements médicamenteux de l’hépatite?C

    Dalibon   Pierre  

    Résumé Le traitement de l’infection par le virus de l’hépatite C (VHC) a considérablement progressé au cours des dernières années avec l’apparition des nouvelles molécules antivirales ciblant spécifiquement et directement le virus. Les bithérapies classiques associant interféron et ribavirine ont évolué vers des trithérapies associant une antiprotéase, puis vers des associations nouvelles, de deux, trois, voire quatre médicaments, s’affranchissant généralement du recours à l’interféron ou à la ribavirine. Ces traitements associent une grande efficacité, une bonne tolérance et une faible durée. Summary Treatment for the hepatitis C virus (HCV) has progressed significantly over recent years with the arrival of new antiviral molecules targeting the virus specifically and directly. Traditional dual therapies combining interferon and ribavirin firstly evolved towards triple therapies combining a protease inhibitor, then towards new combinations of two, three or even four drugs, generally eliminating the use of interferon or ribavirin. These treatments offer high efficacy and good tolerance and are generally short in duration.
    Download Collect
  • Traitements médicamenteux de l’hépatite C

    Pierre Dalibon  

    Résumé Le traitement de l’infection par le virus de l’hépatite C (VHC) a considérablement progressé au cours des dernières années avec l’apparition des nouvelles molécules antivirales ciblant spécifiquement et directement le virus. Les bithérapies classiques associant interféron et ribavirine ont évolué vers des trithérapies associant une antiprotéase, puis vers des associations nouvelles, de deux, trois, voire quatre médicaments, s’affranchissant généralement du recours à l’interféron ou à la ribavirine. Ces traitements associent une grande efficacité, une bonne tolérance et une faible durée. Summary Treatment for the hepatitis C virus (HCV) has progressed significantly over recent years with the arrival of new antiviral molecules targeting the virus specifically and directly. Traditional dual therapies combining interferon and ribavirin firstly evolved towards triple therapies combining a protease inhibitor, then towards new combinations of two, three or even four drugs, generally eliminating the use of interferon or ribavirin. These treatments offer high efficacy and good tolerance and are generally short in duration.
    Download Collect
  • In vivo imaging of C. elegans endocytosis.

    Wang, Lei   Audhya, Anjon  

    Over the past decade, the early Caenorhabditis elegans embryo has proven to be a useful animal model to study a variety of membrane trafficking events, at least in part due to its large size, optical transparency, and ease of manipulation. Importantly, the stereotypic nature of membrane remodeling that occurs during early embryogenesis has enabled quantitative measurement of endocytic flux. In the absence of exogenous stimulation, resumption of the cell cycle triggered by fertilization is coupled to a dramatic redistribution of plasma membrane content. Numerous proteins are rapidly internalized via clathrin-mediated endocytosis, and the fate of these cargoes can be followed precisely using live imaging in utero. Key to these studies is the maintenance of animal health and their immobilization, which can become technically challenging during extended imaging sessions. Here we highlight recent advances in live imaging techniques that have facilitated the interrogation of endocytic transport in live animals. We focus on the use of transgenic C. elegans strains that stably express fluorescently-tagged proteins, including components of the endosomal system and cargo molecules that traverse this network of membranes. Our findings demonstrate the utility of the C. elegans embryo in defining regulatory mechanisms that control the numerous steps of endocytic trafficking. Copyright =C2=A9 2014 Elsevier Inc. All rights reserved.
    Download Collect
  • Carcinoma de c=C3=A9lulas de Merkel: Estudio de 3 casos

    Vila Blanco, Julio Miguel   Nabhan, Said  

    Aim: Our purpose was to report on three patients having Merkel cell carcinoma (MCC). This tumor is a trabecular carcinoma or undifferentiated small cell carcinoma of the skin. It represents a rare and well-defined characteristic neoplasm, associated with radiation, immunosuppression and recently with the polyomavirus. Material and methods: Descriptive clinical study of three adult patients treated between 2011 and 2013 in our center either in the General Surgery Department or Oral Surgery Department. There were two men (50 and 79 years) and one woman (79 years). Results: The youngest man presented with a right inguinal lymph node. The primary lesion was not found. The second male patient had been on infliximab therapy due inflammatory bowel disease and had a lesion on the inferior lip. The single female patient had a right pretibial lesion. Diagnosis was made by means of immunohistochemical analysis of biopsies (CAM 5.2 and CK-20 positive, TTF-1 negative, chromogranin and NSE positive intermediate 2 and 1). In all three cases surgery and sentinel node technique was performed. After surgery, treatment was continued with adjuvant chemotherapy in two patients. Radiotherapy was applied to the patient who had been on infliximab therapy. This patient ultimately died. Conclusions: MCC is a rare tumor. It occurs in adult patients with distinct clinical features. It has to be suspected to allow an early diagnosis. Diagnosis is made by biopsy and it is confirmed by immunohistochemistry. Surgery with the sentinel node technique is the usual treatment, besides adjuvant chemoradiotherapy it is also applied.=09
    Download Collect
  • Tracking Bioluminescent ETEC during In vivo BALB/c Mouse Colonization

    Rodea, Gerardo E.   Montiel-Infante, Francisco X.   Cruz-Cordova, Ariadnna   Saldana-Ahuactzi, Zeus   Ochoa, Sara A.   Espinosa-Mazariego, Karina   Hernandez-Castro, Rigoberto   Xicohtencatl-Cortes, Juan  

    Enterotoxigenic Escherichia coli (ETEC) is a leading cause of diarrhea worldwide. Adhesion to the human intestinal tract is crucial for colonization. ETEC adhesive structures have been extensively studied; however, colonization dynamics remain uncharacterized. The aim of this study was to track bioluminescent ETEC during in vivo infection. The promoter region of dnaK was fused with the luc gene, resulting in the pRMkluc vector. E. coli K-12 and ETEC FMU073332 strains were electroporated with pRMkluc. E. coli K-12 pRMkluc was bioluminescent; in contrast, the E. coli K-12 control strain did not emit bioluminescence. The highest light emission was measured at 1.9 OD600 (9 h) and quantified over time. The signal was detected starting at time 0 and up to 12 h. Streptomycin-treated BALB/c mice were orogastrically inoculated with either ETEC FMU073332 pRMkluc or E. coli K-12 pRMkluc (control), and bacterial colonization was determined by measuring bacterial shedding in the feces. ETEC FMU073332 pRMkluc shedding started and stopped after inoculation of the control strain, indicating that mouse intestinal colonization by ETEC FMU073332 pRMkluc lasted longer than colonization by the control. The bioluminescence signal of ETEC FMU073332 pRMkluc was captured starting at the time of inoculation until 12 h after inoculation. The bioluminescent signal emitted by ETEC FMU073332 pRMkluc in the proximal mouse ileum was located, and the control signal was identified in the cecum. The detection of maximal light emission and bioluminescence duration allowed us to follow ETEC during in vivo infection. ETEC showed an enhanced colonization and tropism in the mouse intestine compared with those in the control strain. Here, we report the first study of ETEC colonization in the mouse intestine accompanied by in vivo imaging.
    Download Collect
  • Tracking Bioluminescent ETEC during In vivo BALB/c Mouse Colonization

    Rodea Gerardo E.   Montiel-Infante Francisco X.   Cruz-Córdova Ariadnna   Salda?a-Ahuactzi Zeus   Ochoa Sara A.   Espinosa-Mazariego Karina   Hernández-Castro Rigoberto   Xicohtencatl-Cortes Juan  

    Download Collect
  • Pediatric Intensive Care: Immunomodulation With Activated Protein C ex vivo

    Eliwan, Hassan O.   Watson, William R. G.   Regan, Irene   Philbin, Brian   O'Hare, Fiona M.   Strickland, Tammy   O'Neill, Amanda   O'Rourke, Michelle   Blanco, Alfonso   Healy, Martina   Nolan, Beatrice   Smith, Owen   Molloy, Eleanor J.  

    Download Collect
  • Maturation extracellulaire du virus de l’hépatite C

    Chanut, Marion   Granier, Christelle   Cosset, François-Loïc   Denolly, Solène  

    Download Collect
  • In vitro and in vivo evaluation of syntaxin-specific BoNT/C

    Giulia Zanetti   Marco Pirazzini   Ornella Rossetto   Aram Megighian   Tina Henke   Andreas Rummel   Thomas Binz   Cesare Montecucco  

    Download Collect
  • Miocarditis de c=C3=A9lulas gigantes

    Carrera, Tito A.   Jaimes, Claudia   Rodr=C3=ADguez, Diego  

    Abstract Giant cell myocarditis is a rare condition with a great impact with regards to mortality of otherwise young and healthy patients, causing multiple clinical presentations, such as heart failure, refractory ventricular arrhythmias and blocks. Its diagnosis is reached with a high degree of suspicion and with the confirmation by means of a endomyocardial biopsy with the presence of multinucleated giant cells without a granulomatous pattern. Its immunomodulatory treatment has considerably changed during the last years, with a clear reduction in mortality rates, though complementary management strategies are still required, such as the use of intracardiac devices and/or heart transplantation in order to achieve better longterm results.=09
    Download Collect
  • A Conversation with Frans C. De Schryver

    Hofkens, Johan   Kamat, Prashant V.  

    Download Collect
  • Au c?ur de la cardiomyopathie diabétique

    Lugat Alexandre   Joubert Michael   Cariou Bertrand   Prieur Xavier  

    Download Collect
  • De verbinding tussen P&C en capaciteitsmanagement

    Wolters, Pieter  

    Download Collect
  • C?ur et sexe, quoi de neuf??

    Colson, M.H.   Cuzin, B.   Faix, A.   Grellet, L.   Huyghes, E.  

    Download Collect
  • Brèves : Hépatite C, facteur de risque de Parkinson ?

    Download Collect
1 2 3 4 5 6 7 8 9 10

Contact

If you have any feedback, Please follow the official account to submit feedback.

Turn on your phone and scan

Submit Feedback